News & Events Press Releases April 13, 2021Kyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer January 13, 2020Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences Media Inquiries To learn more about Kyverna’s work developing cell therapy for inflammatory and autoimmune disease, please reach out to us at: media@kyvernatx.com
